by Katrina Carr | Jan 15, 2020 | Diagnosis & Therapy
Treatment landscape changes but challenges persist for ROS1 or NTRK fusion–positive lung cancer BY ANDREW D. BOWSER MDedge News Patients with non–small cell lung cancer harboring ROS1 or NTRK fusions may face a particularly challenging journey. These cancers, while...
by Katrina Carr | Dec 9, 2019 | Biomarkers
Emerging biomarkers may better guide NSCLC immunotherapy BY SUSAN LONDON credit: TheVisualMD/Science Source Emerging biomarkers hold promise for better selecting patients with non–small cell lung cancer (NSCLC) who are good candidates for immune checkpoint inhibitors,...
by Katrina Carr | Nov 4, 2019 | Diagnosis & Therapy
Adding durvalumab to EP for ES-SCLC improves overall survival BY SHARON WORCESTER Adding durvalumab immunotherapy to etoposide and platinum (EP) for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved 18-month overall...
by Katrina Carr | Nov 4, 2019 | Cost & Coping
Durvalumab maintains NSCLC patient-reported outcomes BY WILL PASS Durvalumab provides clinically meaningful improvements in non–small cell lung cancer (NSCLC) without diminishing patient-reported outcomes (PROs), based on data from the phase 3 PACIFIC trial. This...
by Katrina Carr | Oct 30, 2019 | Diagnosis & Therapy
Maintenance immunotherapy fails in SCLC BY WILL PASS MDedge News Maintenance immunotherapy offers no added survival benefit in patients with extensive disease small cell lung cancer (ED-SCLC), according to results from the CheckMate 451 trial. The phase 3 results...
